Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-10390 in chronic kidney disease
CTR20261558Phase 2Active
- Sponsor
- Changzhou Hengbang Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10390 in chronic kidney disease (CKD), sponsored by Changzhou Hengbang Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
HS-10390
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20261558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261558.